Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

18 Solvay Global Annual Report 2005 Flagship products in 2005 With the acquisition of Fournier Pharma, the Group’s fl agship product is now fenofi brate, sold as TRICOR ® in the United States and primarily as LIPANTHYL ® elsewhere in the world. ANDROGEL ® , a male hormone product, is the second best-performing product after fenofi brate. MARINOL ® , INFLUVAC ® , SERC ® , TEVETEN ® and CREON ® , have all seen remarkable growth rates of between 25 and 33%. Pharmaceuticals Sector Therapeutic fi eld Products Markets 2005 sales % of 2005 Difference in EUR sales 2005/2004 million % Cardiometabolics TriCor ® /Lipanthyl ® Global 185 8% – (5 months) (5 months) Men’s health Androgel ® North America + Central and E. 239 11% +3% Gastroenterology Pantoloc Europe, Middle East, S. Africa ®[1] Canada 166 7% +19% Pancreatic enzymes Creon ® Global 162 7% +25% Neuroscience Serc ® Europe + Export 122 5% +27% Flu vaccines Infl uvac ® Europe + Export 100 4% +32% Cardiometabolics Teveten ® Global [3] 91 4% +26% Women’s health Estratest ® North America 91 4% -9% Gastroenterology Duphalac ® Europe + Export 85 4% +9% Neuroscience Marinol ® USA 84 4% +33% Neuroscience Luvox ® Japan + Export 80 4% +4% Women’s health Prometrium ®[2] USA 71 3% +20% Women’s health Duphaston ® Europe + Export 62 3% +6% Gastroenterology Duspatal ® Europe + Export 58 3% +5% Cardiometabolics Physiotens ® Europe + Export 52 2% -11% [1] A registered trademark of Altana [2] A registered trade mark of Schering Corp. [3] Except for USA, where rights were transferred to Biovail “ Diabetics have a two to four times higher risk of developing cardiovascular disease than non-diabetics.”
Cardiometabolics Fenofi brate, TRICOR ® and LIPANTHYL ® , to treat cardiovascular ailments Cardiovascular disease remains a major world health problem. Fenofi brate joined the Solvay Pharmaceuticals portfolio with the acquisition of Fournier Pharma in July 2005. We are pleased to announce that these products, marketed under the brand names TRICOR ® (by Abbott in the United States) and LIPANTHYL ® (by Solvay Pharmaceuticals in many other countries), have today become Solvay Pharmaceuticals’ largest line and have already attained blockbuster status (annual sales above USD one billion). Fenofi brate is used to treat lipidic disorders like mixed dyslipidemia, characterized by abnormal fat levels, including cholesterol and triglycerides, in the bloodstream. 2005 saw the completion of the key FIELD (“Fenofi brate Intervention and Event Lowering in Diabetes”) study of fenofi brate in a population of type 2 diabetes patients, who have a two to four times higher risk of developing cardiovascular disease than non-diabetics. The post-heart-attack mortality rate in this group is high and reduces average life expectancy by 5 to 10 years. This study is the largest research effort ever aimed at preventing cardiovascular disease among diabetics. Nearly 10 000 patients received either fenofi brate or a placebo over an average fi ve-year period. Initial results were presented in November 2005 at the annual American Heart Association (AHA) congress at Dallas, Texas. FIELD demonstrated favourable clinical effects among type 2 diabetes sufferers without prior histories of cardiovascular disease, among whom fenofi brate reduces by 25% the risk of Pharmaceuticals Sector coronary disease. Fenofi brate intake has lowered by 30% the number of cases where patients have had to undergo laser retina treatment. Even though the study’s main endpoint was not met, it none-theless demonstrated generally good fenofi brate tolerance when administered alone or in combination with other agents including statins. In addition, the combined favourable microvascular effects (retinal and other) and macrovascular effects (such as reducing heart attacks) that were observed for the fi rst time open the way to new uses, alone or in combination with other medicines. OMACOR ® extends Solvay’s cardiology portfolio in Asia In October 2005, Solvay Pharmaceuticals and Pronova Biocare (Norway) signed a new licence and supply contract for OMACOR ® . This agreement signifi cantly extends the sales territory of Solvay’s OMACOR ® range, already marketed in greater Europe and the Middle East, to include Asia and New Zealand. OMACOR ® contains high-purity ethyl esters of Omega 3 acid. It has been registered by Pronova/ Solvay Pharmaceuticals in over 30 countries as an additional secondary prevention treatment following heart attacks and for treating high blood triglycerides counts. Pharmaceuticals 19 Solvay Global Annual Report 2005
Page 1 and 2: Driven by the future Growth, Compet
Page 3 and 4: Highlights January 2005 Solvay fi n
Page 5 and 6: Activities Group sales 2005 = EUR 8
Page 7 and 8: Our Vision - Independent industrial
Page 9 and 10: here to stay, in our view irreversi
Page 11 and 12: Board of Directors and Corporate Go
Page 13 and 14: 4 Executive Committee and General M
Page 15 and 16: Such a strategy is possible only wi
Page 17 and 18: Specialities Solvay Specialties fro
Page 19 and 20: Key fi gures [EUR million] Pharmace
Page 21: Cardiometabolic Cardiovascular dise
Page 25 and 26: “ DUODOPA® entered Solvay’s pr
Page 27 and 28: Pharmaceuticals Sector Therapeutic
Page 29 and 30: Key fi gures [EUR million] Chemical
Page 31 and 32: Growth To speed up its growth, the
Page 33 and 34: Initiatives have also been launched
Page 35 and 36: “ The ‘Soil Remediation Reagent
Page 37 and 38: Key fi gures [EUR million] Plastics
Page 39 and 40: Innovation “Twin-Sheet Blow Mould
Page 41 and 42: Plastics 37 Solvay Global Annual Re
Page 43 and 44: which it was able to take advantage
Page 45 and 46: New Business Development Priority t
Page 47 and 48: Meeting The Science Days organized
Page 49 and 50: Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74:
and the estimated fi nancial conseq
Page 75 and 76:
The deferred taxes recorded in the
Page 77 and 78:
2005 Millions EUR Acquisitions Disp
Page 79 and 80:
Neopharma On January 19, 2005 the S
Page 81 and 82:
(around 300 persons) with a view to
Page 83 and 84:
In 2005 the impairment tests on goo
Page 85 and 86:
Solvay Group purchased 100% of the
Page 87 and 88:
Post-employment benefi t plans are
Page 89 and 90:
Actuarial assumptions used in deter
Page 91 and 92:
Analysis of total fi nancial debt b
Page 93 and 94:
In this way, at the end of 2005, th
Page 95 and 96:
The following amounts relating to J
Page 97 and 98:
PORTUGAL Fournier Farmaceutica Port
Page 99 and 100:
List of fully consolidated Group co
Page 101 and 102:
Solvay Salz Holding GmbH, Hannover
Page 103 and 104:
CANADA Fournier Pharma, Inc., Montr
Page 105 and 106:
GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108:
Summary fi nancial statements of So
Page 109 and 110:
Statutory auditor’s report to the
Page 111 and 112:
The Solvay share compared with the
Page 113 and 114:
Contacts: The Investor Relations Te
Page 115 and 116:
Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

Create successful ePaper yourself

Delete template?

Save as template?